Secretory Leukocyte Protease Inhibitor (SLPI)—A Novel Predictive Biomarker of Acute Kidney Injury after Cardiac Surgery: A Prospective Observational Study
<b> </b>Acute kidney injury (AKI) is one of the most frequent complications after cardiac surgery and is associated with poor outcomes. Biomarkers of AKI are crucial for the early diagnosis of this condition. Secretory leukocyte protease inhibitor (SLPI) is an alarm anti-protease that ha...
Main Authors: | Luisa Averdunk, Christina Fitzner, Tatjana Levkovich, David E. Leaf, Michael Sobotta, Jil Vieten, Akinobu Ochi, Gilbert Moeckel, Gernot Marx, Christian Stoppe |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2019-11-01
|
Series: | Journal of Clinical Medicine |
Subjects: | |
Online Access: | https://www.mdpi.com/2077-0383/8/11/1931 |
Similar Items
-
Oral secretory leukocyte protease inhibitor (SLPI): Associations with oropharyngeal cancer and treatment outcome.
by: Brittney L Dickey, et al.
Published: (2021-01-01) -
Mucosal Progranulin expression is induced by <it>H. pylori</it>, but independent of Secretory Leukocyte Protease Inhibitor (SLPI) expression
by: Treiber Gerhard, et al.
Published: (2011-05-01) -
Increased secretory leukocyte protease inhibitor (SLPI) production by highly metastatic mouse breast cancer cells.
by: Kevin T Sayers, et al.
Published: (2014-01-01) -
Anti-Protease Activity Deficient Secretory Leukocyte Protease Inhibitor (SLPI) Exerts Cardioprotective Effect against Myocardial Ischaemia/Reperfusion
by: Kijtawornrat, A., et al.
Published: (2022) -
Secretory leukocyte protease inhibitor (SLPI) is, like its homologue trappin-2 (pre-elafin), a transglutaminase substrate.
by: Kévin Baranger, et al.
Published: (2011-01-01)